Covington Capital Management’s ImmunityBio IBRX Stock Holding History

Covington Capital Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1K	Buy	+250	New	+$1.14K	﹤0.01%	1125

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Covington Capital Management's IBRX Position: Q3 2022 in Review

Covington Capital Management opened a new position in ImmunityBio (IBRX) in Q3 2022: 250 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1125 among its holdings.

126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

Covington Capital Management held 250 shares of ImmunityBio worth $1K as of Q3 2022.
ImmunityBio was a new Covington Capital Management position in Q3 2022.
ImmunityBio made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #1125 holding.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.